Avidity Bioscience Announces Proposed Public Offering Of $300M Of Common Stock
Portfolio Pulse from Benzinga Newsdesk
Avidity Bioscience has announced a proposed public offering of $300 million of common stock. This move is likely aimed at raising capital for ongoing and future projects.
June 12, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avidity Bioscience's proposed public offering of $300 million in common stock is likely to dilute existing shares, potentially leading to a short-term decrease in stock price.
The announcement of a $300 million public offering will likely dilute the value of existing shares, leading to a short-term decrease in stock price as the market adjusts to the increased supply of shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100